18 completed. 18 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 18 |
| Phase 2 | 5 | Completed 5 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DT2216 in Relapsed/Refractory Malignancies DT2216 - Solid Tumor, Hematologic Malignancy | Phase 1 | Completed | Dialectic Therapeutics, Inc | 20 | 2021-08-25 | 2025-04-16 |
| GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor Eliglustat, Immune checkpoint inhibitor - Solid Tumor, Hematologic Malignancy | Phase 1 | Completed | Chinese PLA General Hospital | 31 | 2021-07-01 | 2023-12-19 |
| Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies PBCAR19B - CD19 Expressing Malignancies, Hematologic Malignancy | Phase 1 | Completed | Precision BioSciences, Inc. | 13 | 2021-06-16 | 2024-07-26 |
| A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy IBI322 - Hematologic Malignancy | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 70 | 2021-05-07 | 2024-11-06 |
| Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy Prophylactic Donor lymphocytes infusions, Preventive Donor lymphocytes infusions - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-04-01 | 2024-06-25 |
| CAR-37 T Cells in Hematologic Malignancies CAR-37 T cells - Hematologic Malignancy, Leukemia | Phase 1 | Completed | Marcela V. Maus, M.D.,Ph.D. | 6 | 2020-06-19 | 2024-12-12 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels Tazemetostat, Itraconazole, Rifampin - All Malignancies, Advanced Malignancies | Phase 1 | Completed | Epizyme, Inc. | 42 | 2020-04-23 | 2025-02-19 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Ain Shams University | 24 | 2019-03-01 | 2023-08-22 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 CPX-351 - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 21 | 2018-11-20 | 2021-07-22 |
| Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant Transplantation of cord blood expanded with UM171 - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Maisonneuve-Rosemont Hospital | 25 | 2015-12-16 | 2019-08-05 |
| A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies BBI608, Dexamethasone, Bortezomib - Hematologic Malignancy | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 15 | 2015-05-01 | 2023-11-14 |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer Romidepsin, Rifampin - Hematologic Malignancy, Malignant Lymphoma | Phase 1 | Completed | Celgene | 14 | 2011-04-01 | 2019-11-25 |
| Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer Romidepsin, Ketoconazole - Hematologic Malignancy, Malignant Lymphoma | Phase 1 | Completed | Celgene | 15 | 2011-04-01 | 2019-11-25 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Ciclopirox Olamine - Hematologic Malignancy, Acute Lymphocytic Leukemia | Phase 1 | Completed | University Health Network, Toronto | 20 | 2009-10-01 | 2015-06-22 |
| A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies P1446A-05 - Solid Tumor, Hematologic Malignancy | Phase 1 | Completed | Piramal Enterprises Limited | 29 | 2008-12-01 | 2012-11-21 |
| Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies haplo/cord transplant - Hematologic Malignancy, Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | Completed | Joanne Kurtzberg, MD | 3 | 2007-08-01 | 2015-04-03 |
| Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant Infusion of donor dendritic cells, Infusion of donor lymphocytes - Hematologic Malignancy | Phase 1 | Completed | Dana-Farber Cancer Institute | 25 | 2003-07-01 | 2012-03-29 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases ANTI-CD45, CAMPATH-1H, FK506 - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 24 | 2002-11-01 | 2012-06-29 |
Hematologic Neoplasms (18) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Aplastic (2) · Hodgkin Disease (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Multiple Myeloma (2) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Graft vs Host Disease (1)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Neoplasms (18) · Neoplasms by Site (18) · Immune System Diseases (9) · Neoplasms by Histologic Type (9) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Bone Marrow Diseases (5) · Chronic Disease (4) · Disease Attributes (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Leukemia, Myeloid (4)
Rifampin (2) · romidepsin (2) · Alemtuzumab (1) · Bortezomib (1) · CPX-351 (1) · Ciclopirox (1) · DT2216 (1) · Dexamethasone (1) · Imatinib Mesylate (1) · Immune Checkpoint Inhibitors (1) · Itraconazole (1) · Ketoconazole (1) · Tacrolimus (1) · Whole-Body Irradiation (1) · eliglustat (1)
Celgene (2) · Ain Shams University (1) · Baylor College of Medicine (1) · Chinese PLA General Hospital (1) · Dana-Farber Cancer Institute (1) · Dialectic Therapeutics, Inc (1) · Epizyme, Inc. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Jazz Pharmaceuticals (1) · Joanne Kurtzberg, MD (1) · Maisonneuve-Rosemont Hospital (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Piramal Enterprises Limited (1) · Precision BioSciences, Inc. (1) · St. Petersburg State Pavlov Medical University (1)
United States (11) · Canada (3) · China (2) · United Kingdom (2) · Egypt (1) · India (1) · Russia (1) · Spain (1)
Ken Takeshita, MD (2) · Anish Maru, D.M. (1) · Edwin Alyea, MD (1) · Joanne Kurtzberg, MD (1) · Malcolm K Brenner, MD (1) · Manal H Elsayed, MD (1) · Mark Minden, MD (1) · Matthew J. Frigault, MD (1) · Michael Kurman, MD (1) · Minish Jain, M.D. (1) · Monika Vainorius, MD (1) · Naresh Somani, D.M. (1) · Sandra Cohen, MD (1) · Shona Nag, M.D. (1)
PMID 22009536, PMID 31704264, PMID 33022376, PMID 37467030, PMID 37925363, PMID 38473278, PMID 38781564, PMID 39293082, PMID 39706761, PMID 41225624